- Home
- MTR vs ALZN Comparison
MTR vs ALZN Comparison
Compare MTR & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | ALZN |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTR | ALZN |
|---|---|---|
| Price | $4.25 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 12.3K | ★ 45.8K |
| Earning Date | 03-31-2026 | 12-09-2025 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $623,288.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $1.88 |
| 52 Week High | $10.42 | $11.70 |
Technical Indicators
Market Signals| Indicator | MTR | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 35.58 |
| Support Level | $4.03 | $1.97 |
| Resistance Level | $4.54 | $2.27 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 23.91 | 3.27 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.